Determination of Walking, Balance, Fall Risk and Kinesiophobia in Individulas with Alzheimer's Dementation

THE OBJECTIVE OF THE RESEARCHERS IS TO DETERMINE WALKING, BALANCE, FALL RISK AND KINESIOPHOBIA IN INDIVIDUALS WITH ALZHEIMER'S DEMENTATION.

Study Overview

• Status: Completed
• Conditions: Alzheimer Disease
• Intervention / Treatment: Other: balance tests,questionnaire

Detailed Description

The gait, balance, fall risks and kinesiophobia of individuals with Alzheimer's Dementia will be evaluated and compared with healthy individuals.

• Study Type: Observational
• Enrollment (Actual): 41

Contacts and Locations

Study Locations

• Turkey
  • Kırıkkale, Turkey
    • Kırıkkale University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

36 individual

Description

Inclusion Criteria:

• INDEPENDENT walker diagnosed with Alzheimer's Dementia

Exclusion Criteria:

• Having a disability to do physical activity Those who have had an operation in the last 6 months

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
INDIVIDUALS WITH ALZHEIMER; balance and gait will be evaluated survey questions will be asked	Other: balance tests,questionnaire; Individuals will be tested and recorded.
HEALTHY INDIVIDUALS; balance and gait will be evaluated survey questions will be asked	Other: balance tests,questionnaire; Individuals will be tested and recorded.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Age	between the ages of 50 and 80	5 month
Body Mass Index	BMI was recorded in kg/m^2	5 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Tinetti Gait and Balance Test (TGBT)	TGBT consists of balance and gait subheadings. For balance, there are 13 items, and 9 items for gait. Items are scored as 0 (abnormal), 1 (adaptive) and 2 (normal) for balance, 0 (abnormal), 1 (normal) for gait. The maximum balance score of the patient is 26 and the maximum gait score is 9. Total score (balance + walking) is 35 points.	5 month
Mini Mental State Test	It was used to determine the cognitive state before the training. The Mini-Mental State Test was first published by Folstein et al. It consists of eleven items under 5 main headings: orientation, record memory, attention and calculation, recall and language, and the total score is evaluated over 30 points.	5 month
Tampa Scale	17 questions is a scale. The scale is used in work-related activities, injury/re-injury and fear-avoidance contains the parameters.	5 month
The Time Up Go Test	The timed "Up & Go" measures, in seconds, the time taken by an individual to stand up from a standard arm chair (approximate seat height of 46 cm), walk a distance of 3 meters, turn, walk back to the chair, and sit down again.	5 month
The Gait Speed Measurement Test (GSMT)	For GSMT, individuals were asked to walk at a speed they wanted on a flat surface of 14 m. Signs were placed on the 2nd and 12th meters of the test area to minimize the speed changes between walking start and walking finish, and to make a more objective measurement. The walking time at this 10-meter distance was measured with the stopwatch and the results were recorded in sec and the walking speed was determined.	5 month
Fall Risk Self-Assessment Scale	It consists of 13 items assessing the risk of falling in the elderly. The answers are yes (1 point) and no (0 points), and individuals who get 4 points or more from the scoring are classified as having a high risk of falling.	5 month

Collaborators and Investigators

• Sponsor: Kırıkkale University
• Investigators: Study Chair: Oğuzhan Doğancı, Kırıkkale University

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2022
• Primary Completion (Actual): June 1, 2022
• Study Completion (Actual): November 1, 2022

Study Registration Dates

• First Submitted: December 7, 2021
• First Submitted That Met QC Criteria: January 9, 2022
• First Posted (Actual): January 21, 2022

Study Record Updates

• Last Update Posted (Actual): December 3, 2024
• Last Update Submitted That Met QC Criteria: November 29, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurocognitive Disorders; Dementia; Tauopathies; Neurodegenerative Diseases; Phobic Disorders; Anxiety Disorders; Kinesiophobia; Alzheimer Disease
• Other Study ID Numbers: kku-oguzhandoganci1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: test results of individuals, information such as height and weight will be published.
• IPD Sharing Time Frame: 1.03.2022-1.07.2022
• IPD Sharing Access Criteria: open access
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No